Socrus Bio Sciences said its board of directors would meet on October 14 to consider reduction of capital based on audit committee recommendations.
In a filing to the exchanges, the company said that on Tuesday, the board decided to consider reduction of capital of the company up to 95 per cent of the paid up capital against accumulated losses.